BPC 157s Effect on Healing
In the SURMOUNT-1 trials, the tirzepatide group lost about 20.2% of baseline body weight in 72 weeks, while the semaglutide group lost about 13.7 %
Combination therapy was considered appropriate for adults with persistent kidney disease progression, high cardiovascular risk or suboptimal metabolic control
Additionally, the study found that the decrease in muscle mass with GLP-1s was several times greater than what is expected from age-related muscle loss
Should I adjust my other diabetes medications when changing Ozempic timing
Meanwhile, Hanyu Pharmaceutical confirmed that Phase III clinical trials for both weight management and hypoglycemic indications of semaglutide have been initiated, with all subjects already enrolled, receiving dosing and follow-ups, and entering the final stage, with clinical trials expected to be completed within 2025